Inobrodib

Tier C — Watch / trade

Inobrodib

Cellcentric Ltd

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：CREBBP, p300

Indications (approved)：Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndrome, Acute myeloid leukaemia, Peripheral T-cell lymphoma, Haematological malignancy, Non-small cell lung cancer, Castration-resistant prostate cancer

Regional status

Phase III

2026-08-01

Phase II

2018-07-23

China

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Inobrodib?

Approved indications include: Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndrome, Acute myeloid leukaemia, Peripheral T-cell lymphoma, Haematological malignancy, Non-small cell lung cancer, Castration-resistant prostate cancer.

When does the Inobrodib patent expire?

No public expiry year is available for Inobrodib yet; this page updates once verified.

How do I get a quote for Inobrodib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29